

## 6 Literaturverzeichnis

Aaronson SA. Growth factors and cancer. *Science* 1991; 25: 1146-1153

Agus DB, Scher HI, Higgins B, Fox WD, Heller G, Fazzari M, Cordon-Cardo C, Golde DW. Response of prostate cancer to anti-HER-2/neu antibody in androgen-dependent and-independent human xenograft models. *Cancer Res* 1999 Oct 1; 59(19): 4761-4

Alimandi M, Wang L-M, Bottaro D, Lee C-C, Kuo A, Frankel M et al. Epidermal growth factor and betacellulin mediate signal transduction through co-expression of erb B-2 and erb B-3 receptors. *EMBO J* 1997; 16: 5608-5617

Alimandi M, Romano A, Curia MC et al. Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas. *Oncogene* 1995; 10: 1813-1821

Alroy I, Yarden Y. The erb B signaling network in embryogenesis and oncogenesis: signal diversification through combinatoric ligand-receptor interactions. *FEBS Letters* 1997; 410: 83-86

Altavilla G et al. Prognostic significance of epidermal growth factor receptor (EGFR) and c-erb B-2 protein overexpression in adenocarcinoma of the uterine cervix. *Eur J Gynaecol Oncol* 1996; 17: 267-70

Baselga J et al. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. *Oncology (Huntingt)*. 1997; 11: 43-8

Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NZ, Seidman AC, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185 HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. *J Clin Oncol* 1996; 14: 737-744

Baulida J, Kraus MH, Alimandi M, DiFiore PP, Carpenter G. All erb B-receptors other than the epidermal growth factor receptor are endocytosis impaired. *J Biol Chem* 1996; 271: 5251-5257

Berli RR, Hynes NE. Epidermal growth factor-related peptides activate distinct subsets of erb B-receptors and differ in their biological activities. *J Biol Chem* 1996; 271: 6071-6076

Berchuck A, Rodriguez G, Kamel A, Soper JT, Clark-Pearson DL, Bast RC. Expression of epidermal growth factor receptor and Erb B-2 in normal and neoplastic cervix, vulva and vagina. *Obstet Gynecol* 1990; 76: 381-387

Bishop JM. Molecular themes in carcinogenesis. *Cell* 1991; 64: 235-248

Bosher JM, Williams T and Hurst HC. The developmentally regulated transcription factor AP-2 is involved in c-erbB-2 overexpression in human mammary carcinoma. *Proc Natl Acad Sci USA* 1995; 92: 744-747

Brandt R et al. Growth inhibitors for mammary epithelial cells. *Prog Mol Subcell Biol*. 1998; 20: 197-248

Brumm C, Riviere A, Wilckens C. and Loning T. Immunohistochemical investigation and northern blot analysis of c-erb B-2 expression in normal, premalignant and malignant tissues of the corpus and cervix uteri. *Virchows Arch. A Pathol. Anat. Histopathol.* 1990; 417: 477-484

Brunton VG, Carlin S, Workman P. Alterations in EGF-dependent proliferative and phosphorylation events in squamous cell carcinoma cell lines by a tyrosine kinase inhibitor. *Anticancer Drug Des* 1994; 9: 311-329

Campbell ID, Bork P. Epidermal growth factor-like modules. *Curr Opin Structural Biol* 1993; 3: 385-392

Cannistra S.A. and Niloff J.M. Cancer of the uterine cervix. *N. Engl. J. Med.* 334, 1030-1038, 1996

Carter WB. HER2 signaling-induced microvessel dismantling. *Surgery* 2001; 130: 382-387

Chang JL, Tsao YP, Liu DW, Han CP, Lee WH, Chen SL. The expression of type I growth factor receptors in the squamous neoplastic changes of uterine cervix. *Gynecol Oncol* 1999; 73(1): 62-71

Chazin VR, Kaleko M, Miller AD and Slamon DJ. Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor. *Oncogene* 1992, 7: 1859-1866

Ciardiello F and Tortora, G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. *Clin Cancer Res* 2001; 7: 2958-2970

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scgoll S, Fehrenbach L, Wolter JM, Paton V, Shak S, Liberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. *J Clin Oncol* 1999; 17: 2639-2648

Cohen BD, Siegall CB, Bacus S, Foy L, Green JM, Hellström I, Hellström KE, and Fell HP. Role of epidermal growth factor receptor family members in growth and differentiation in breast carcinoma. *Biochem. Soc. Symp.* 1998; 63: 199-210

Cordell J, Fallini BM, Erber WN et al. Immunoenzymatic labeling of monoclonal antibodies using immune complex of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). *J Histochem Cytochem* 1984; 32: 219-229

Costa MJ, Walls J and Trelford JD. c-erb B-2 oncoprotein overexpression in uterine cervix carcinoma with glandular differentiation. A frequent event but not an independent prognostic marker because it occurs late in disease. *Am. J. Clin. Pathol.* 1995; 104: 634-642

Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, Levinsin A, Ullrich A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. *Science* 1985; 230: 1132-1139

Creek KE, Geslani G, Batova A and Pirisi L. Progressive loss of sensitivity to growth control by retinoid acid and transforming growth factor-beta at late stages of human-papillomavirus-type-16-initiated transformation of human keratinocytes. *Advanc exp Med Biol* 1995; 375: 117-135

Dewit L. Combined treatment of radiation and cisdiamminedichloroplatinum (II): a review of experimental and clinical data. *Int J Radiat Oncol Biol Phys* 1987; 13: 403-26

Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. erb B-2 is a potent oncogene when overexpressed in NIH/3T3 cells. *Science* 1987; 237: 178-182

Eiermann W. (Internationale Herceptin-Studiengruppe): Trastuzumab combined with chemotherapy for the treatment of HER2-positve metastatic breast cancer: Pivotal trial data. *Ann Oncol* 2001; 12: 57-62

Falls DL, Rosen KM, Corfas G, Lane WS, Fischbach GD. ARIA, a protein that stimulates acetylcholines receptor Synthesis, is a member of the Neu ligand family. *Cell* 1993; 72: 801-815

Filmus J, Pollak MN, Cailleau R and Buick RN. MDA 468, a human breast cancer cell line with a high number of epidermal growth factor (EGF) receptors, has an amplified EGF receptor gene and ist growth inhibited by EGF. *Biochem Biophys Res Commun* 1985; 128: 898-905

Forminaya J et al. A chimeric fusion protein containing transforming growth factor-alpha mediates gene transfer via binding to the EGF receptor. *Gene Ther.* 1998; 5: 521-30

Fry DW, Bridges AJ, Denny WA, Doherty A, Greis KD, Hicks JL, Hook KE, Keller PR, Leopold WR, Loo JA, McNamara DJ, Nelson JM, Sherwood V, Smaill JB, Trumpp-Kallmeyer S, Dobrusin EM. Specific, irreversible inactivation of the epidermal growth factor receptor and c-erb B-2, by a new class of tyrosine kinase inhibitors. *Proc Natl Acad Sci USA* 1998; 95: 12022-12027

Gamett DC, Pearson G, Cerione RA, Friedberg I. Secondary dimerization between members of the epidermal growth factor receptor family. *J Biol Chem* 1997; 272: 12022-12027

Garner A. Therapeutic potential of growth factors and antagonists. *Yale J Biol Med.* 1992; 65: 715-23; discussion 737-40

- Gilbertson RJ, Clifford SC, MacMeekin W, Wright C, Perry H, Kelly P, Pearson ADJ, Lunec J. Expression of the ErbB-Neuregulin Signaling Network during Human Cerebellar Development: Implications for the Biology of Medulloblastoma. *Canc Res* 1998; 58: 3932-3941
- Gilbertson RJ, Perry RH, Kelly PJ, Pearson AD and Lunec J. Prognostic significance of HER2 and HER4 coexpression in childhood medulloblastoma. *Cancer Res.* 1997; 57: 3272-3280
- Gill GN and Lazar CS. Increased phosphotyrosine content and inhibition of proliferation in EGF treated A431 cells. *Nature* 1981; 293: 305-307
- Goeppinger A, Wittmaack FM, Wintzer HO, Ikenberg H, Bauknecht T. Localization of human epidermal growth factor receptor in cervical intraepithelial neoplasias. *J Cancer Res Clin Oncol* 1989; 115: 259-263
- Goustin AS, Leof EB, Shipley GD, Moses HL. Growth factors and cancer. *Cancer Res* 1986; 46: 1015-1029
- Graus-Porta D, Beerli RR, Daly JM, Hynes NE. Erb-B2, the preferred heterodimerization partner of all erb B-receptors, is a mediator of lateral signaling. *EMBO J* 1997; 16: 1647-1655
- Groenen LC, Nice EC, Burgess AW. Structure-function relationship for the EGF/TGF- $\alpha$  family mitogens. *Growth Factors* 1994; 11: 235-257
- Gullick WJ, Bianco C, Normanno N et al. Growth factors and their receptors: a novel approach to the endocrinology of human breast cancer. *Woman & Cancer* 1998; 1: 29-57
- Gullick WJ and Srinivasan R. The type I growth factor receptor family: new ligands and receptors and their role in breast cancer. *Breast Cancer Res. Treat.* 1998; 52: 43-53
- Gullick WJ. The c-erbB3/HER3 receptor in human cancer. *Cancer Surv.* 1996; 27: 339-349
- Guy PM, Platko JV, Cantley C, Cerione RC and Carraway KL. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. *Proc Natl Acad Sci USA* 1994; 91: 3884-3890
- Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J, Wilcox FL. Prognostic value of epidermal growth factor expression in cervical carcinoma. *J Clin Pathol* 1993; 46: 149-153
- Hale RJ, Buckley CH, Gullick WJ, Fox H, Williams J, Wilcox FL. Prognostic value of c-erb B-2 expression in uterine cervical cancer. *J Clin Pathol* 1992; 45: 594-596
- Hamada K, Sakaue M, Alemany R, Zhang WW, Horio Y, Roth JA, Mitchell MF. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. *Gynecol Oncol* 1996; 63: 219-227

- Han H, Landreneau RJ, Santucci TS et al. Prognostic value of immunohistochemical expression of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. *Hum Pathol* 2002; 33: 105-10
- Haugen DR, Akslen LA, Varhaug JE, Lillehaug JR. Expression of c-erbB-3 and c-erb-B-4 proteins in papillary thyroid carcinomas. *Cancer Res* 1996; 56: 1184-1188
- Hayashi Y, Hachisuga T, Iwasaka T, Fukada K, Okuma Y, Yokoyama M and Sugimori H. Expression of res oncogene product and EGF receptor in cervical lymph node involvement. *Gynecol Oncol* 1991; 40: 147-151
- Hidalgo M, Siu LL, Nemunaitis J, Rizzo J, Hammond LA, Takimoto C, Eckhardt SG, Tolcher A, Britten CD, Denis L, Ferrante K, Von Hoff DD, Silbermann S, Rowinski EK. Phase I and II pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. *J Clin Oncol* 2001; 19: 3267-3279
- Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura D, Abadi N, Raab H, Lewis GD. Identification of heregulin, a specific activator of p185erb B2. *Science* 1992; 256: 1205-1210
- Hudziak RM, Schlessinger J, Ullrich A. Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis in NIH 3T3 cells. *Proc Natl Acad Sci USA* 1987; 84: 7159-7163
- Hunt CR, Hale RJ, Armstrong C, Rajkumar T, Gullick WJ and Buckley CH. c-erb B-3 proto-oncogene expression in uterine cervical carcinoma. *International Journal Gynecological Cancer* 1995; 5: 282-285
- Hunter T. Cooperation between oncogenes. *Cell* 1991; 64: 249-270
- Hunter T. The Croonian lecture 1997. The phosphorylation of proteins on tyrosine: its role in cell growth and disease. *Phil Trans R Soc London B* 1998; 353: 583-605
- Hynes N, Stern DF. The biology of erb B-2/neu/HER2 and its role in cancer. *Biochimica et Biophysica Acta* 1994; 198: 165-184
- Jones D.L. and Munger K. Interactions of the human papillomavirus E7 protein with cellcycle regulators. *Sem. Cancer Biol.* 7, 327-337, 1996
- Jones FE, Jerry DJ, Guarino BC, Andrews GC and Stern DF. Heregulin induces in vivo proliferation and differentiation of mammary epithelium into secretory lobuloalveoli. *Cell Growth Differ* 1996; 7: 1031-1038
- Kaplan EL and Meier P. Nonparametric estimation from incomplete observations. *Journal of the American Statistical Association* 1958; 53 . 457-481

Karunagaran D, Tzahar E, Beerli RR, Chen X, Graus-Porta D, Ratzkin BJ, Seger R, Hynes NE, Yarden Y. Erb B-2 is a common auxilliary subunit of NDF and EGF receptors: implications for breast cancer. *EMBO J* 1996; 15: 254-264

Kawamoto T, Mendelsohn J, Le A, Sato GH, Lazar CS and Gill GN. Relation of epidermal growth factor receptor concentration to growth of human epidermoid carcinoma a431 cells. *J Biol Chem* 1984; 259: 7761-7766

Kersemakers AM, Fleuren GJ, Kenter GG, Van den Broek LJ, Uljee SM, Hermans J, Van den Vijver MJ. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor is associated with poor prognosis. *Clin Cancer Res* 1999 Mar; 5(3): 577-86

Kew TY, Bell JA, Pinder SE, Denley H, Srinivasan R, Gullick WJ, Nicholson RI, Blamey RW, Ellis IO. c-erb B-4 protein expression in human breast cancer. *Br J Cancer* 2000; 82(6): 1163-1170

Kim JW, Kim YT, Kim DK, Song CH, Lee JW. Expression of epidermal growth factor receptor in carcinoma of the cervix. *Gynecol Oncol* 1991; 40: 147-151

Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). *Curr Opin Oncol* 2001; 13: 506-513

Kimmig R, Pfeiffer D, Landsmann H, Hepp H. Quantitative determination of the epidermal growth factor receptor in cervical cancer and normal cervical epithelium by 2-color flow cytometry: evidence for downregulation in cervical cancer: *Int J Cancer* 1997; 74: 365-373

King CR, Kraus MH, Aaronson SA. Amplification of a novel v-erb-B-related gene in a human mammary carcinoma. *Science* 1985; 229: 974-976

Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, Yarden Y. The ErbB-2/HER2 oncoprotein of human carcinomas may function as a shared coreceptor for multiple stroma-derived growth factors. *Proc. Natl. Acad. Sci. USA* 1999, Apr 27; 96(9): 4995-5000

Koenders PG, Beex LV, Kienhuis CB, Kloppenborg PW, Benraad TJ. Epidermal growth factor receptor and prognosis in human breast cancer: a prospective study. *Breast Cancer Res Treat* 1993; 25: 21-27

Kornblum HI, Yanni DS, Easterday, MC, Seroogy KB. Expression of the EGF receptor family members ErbB2, ErbB3 and ErbB 4 in germinal zones of the developing brain and in neurosphere cultures containing CNS stem cells. *Dev Neurosci* 2000; 22:16-24

Kraus MH, Issing W, Miki T, Popescu NC, Aaronson SA. Isolation and characterization of erb B-3, a third member of erb B/epidermal growth factor receptor family: evidence for overexpression in a subset of human mammary tumors. *Proc Natl Acad Sci USA* 1989; 86: 9193-9197

Kristensen GB, Holm R, Abeler VM and Trope CG. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erb B-2 in early cervical squamous cell carcinoma. *Cancer* 1996; 78, 433-440

Kury F, Sliutz G, Schemper M, Reiner G, Reiner A, Jakesz R, Wrba F, Zeillinger R, Knogler W, Hubert H and Spona J. HER-2 oncogene amplification and overall survival of breast carcinoma patients. *Eur J Cancer* 1990; 26; 946-949

Lakshmi S, Balaraman Nair M, Jayaprakash PG, Rajalekshmy TN, Krishnan Nair M. and Radhakrishna Pillai M. c-erb B-2 oncoprotein and epidermal growth factor receptor in cervical lesions. *Pathobiology* 1997; 65: 163-168

Langlois NE, Skinner L and Miller ID. C-erb B-2 in cervical carcinoma. *Am. J. Clin. Pathol* 1996; 106: 556-557

Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ, Hurst HC. Expression of the erb B-3 gene product in breast cancer. *Br J Cancer* 1992; 66: 1116-1121

Lemoine NR, Lobresco M, Leung H et al. The erbB-3 gene in human pancreatic cancer. *Journal of Pathology* 1992; 168: 269-273

Li W, Park JW, Nujens A, Sliwkowski MX and Keller GA. Heregulin is rapidly translocated to the nucleus and its transport is correlated with c-myc induction in breast cancer cells. *Oncogene* 1996; 12; 2473-2477

Ling-Mei W, Kuo A, Alimandi M, Veri MC, Lee CC, Kapoor V, Ellmore N, Chen X-H, Pierce JH. Erb B-2-expression increases the spectrum and potency of ligand-mediated signal transduction through erb-B-4. *Proc Natl Acad Sci USA* 1998; 95: 6809-6814

Lofts FJ, Hurst HC, Sternberg MJE, Gullick WJ. Specific short transmembrane sequences can inhibit transformation by the mutant neu growth factor receptor in vitro and in vivo. *Oncogene* 1993; 8: 2813-2820

Loizzi V, Cormio G, Loverro G, Selvaggi L, Disaia PJ, Cappuccini F. Chemoradiation: A new approach for the treatment of cervical cancer. *Int J Gynecol Cancer* 2003 Sept-Oct; 13(5): 580-6

Lyne JC, Melhem MF, Finley GG, Wen D, Liu N, Deng DH and Salup R. Tissue expression of neu differentiation factor/hergulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. *Cancer J. Sci. Am.* 1997; 3: 21-30

Mandai M, Kinishi I, Koshiyama M, Komatsu T, Yamamoto S, Nanbu K, Mori T and Fukumoto M. Altered expression of nm-23 and c-erbB-2 proteins have prognostic significance in adenocarcinoma but not in squamous cell carcinoma of the uterine cervix. *Cancer* 1995; 75: 2523-2529

Marchionni MA, Goodearl AD, Chen MS, Bermingham-McDonogh O, Kirk C, Hendricks M, Danehy F, Misumi D, Sudhalter J, Kobayashi K. Glial growth factors are alternatively spliced erb B-2 ligands expressed in the nervous system. *Nature* 1993; 362: 312-318

Mark HFL, Aswad B, Bassily N, Taylor W, Brown S, Sun CL, Samy M, Zolnierz K, Wong E, Bland K and HSU PH. HER-2/neu gene amplification in stages I-IV breast cancer detected by fluorescent in situ hybridization. *Genetics in Medicine* 1999; 66: 98-103

Mark HFL, Feldman D, Das S, Sun CL, Samy M and Lathrop J. HER-2/neu Oncogene Amplification in Cervical Cancer Studied by Fluorescent in situ Hybridization. *Genetic Testing* 1999; 3(2): 237-242

Marshall CJ. Tumor suppressor genes. *Cell* 1991; 64: 313-326

Maruo T, Yamasaki M, Ladines-Llave CA, Mochzuki M. Immunohistochemical demonstration of elevated expression of epidermal growth factor receptor in the neoplastic changes of cervical squamous epithelium. *Cancer* 1992; 69: 1182-1187

Mason S, Gullick WJ. Type 1 growth factor receptors: an overview of recent developments. *The Breast* 1995; 4: 11-18

Massague J, Pandiella A. Membrane-anchored growth factors. *Ann Rev Biochem* 1993; 62: 515-541

Mitra AB, Murty VV, Pratap M, Sodhani P and Chaganti RS. Erb B2 (HER2/neu) oncogene is frequently amplified in squamous cell carcinoma of the uterine cervix. *Cancer Res.* 1994; 54: 637-639

Morris M, Eifel PJ, Lu J et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. *N Engl J Med* 1999; 340: 1137-43

Nakano T, Oka K, Ishikawa A and Morita S. Correlation of cervical carcinoma c-erb B-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma. *Cancer* 1997; 79: 513-520

Ndubisi B, Sanz S, Lu L, Podczaski E, Benrubi G and Masood S. The prognostic value of HER-2/neu oncogene in cervical cancer. *Ann. Clin. Lab. Science* 1997; 27: 396-401

Nias AH. Radiation and platinum drug interaction. *Int J Radiat Biol Relat Stud Phys Chem Med* 1985; 48: 297-59

Oka K, Nakano T and Arai T. c-erbB-2 oncogene expression is associated with poor prognosis in squamous cell carcinoma of the cervix. *Cancer* 1994; 73: 668-671



Osaki A, Toi M, Yamada H, Kawami H, Kuroi K, Toge T. Prognostic significance of co-expression of c-erb B-2 oncoprotein and epidermal growth factor receptor in breast cancer patients. *Am Surg* 1992; 164: 323-326

Ozanne B, Richards CS, Hendler F, Burns D, Gusterson B. Over-expression of the EGF receptor is a hallmark of squamous cell carcinomas. *J Pathol* 1986; 149: 9-14

Parkes HC, Lillycrop K, Howell A., Craig RK. C-erbB-2 mRNA expression in human breast tumors: comparison with c-erbB-2 DNA amplification and correlation with prognosis. *Br J Cancer* 1990; 61: 39-45

Pearcy R, Brundage M, Drouin P et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. *J Clin Oncol* 2002; 20: 966-72

Pegram MD et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. *J Clin Oncol*. 1998; 16: 2659-71

Pegram MD. Molecular mechanisms underlying the pathology of breast cancer. Symposium „Targeted therapy: The new standards of care in breast cancer?“. San Antonio Breast Cancer Symposium 2001

Peles E, Yarden Y. Neu and its ligands: from an oncogene to neural factors. *BioEssays* 1993;15: 815-824

Perrimon N, Perkins LA. There must be 50 ways to rule the signal: The case of the *Drosophila* EGF receptor. *Cell* 1997; 89: 13-16

Pfeiffer D, Stellwag B, Pfeiffer A, Borlinghaus P, Meier W and Scheidel P. Clinical implications of the epidermal growth factor receptor in the squamous cell carcinoma of the uterine cervix. *Gynecol. Oncol*. 1989; 33: 146-150

Pfeiffer D, Kimmig R, Herrmann J, Ruge M, Fisseler-Eckhoff A, Scheidel P, Jensen A, Schatz H and Pfeiffer A. Epidermal growth factor receptor correlates negatively with cell density in cervical squamous epithelium and is down-regulated in cancers of the uterus. *Int. J. Cancer* 1998; 79: 49-55

Pinion SB, Kennedy JH, Miller RW and MacLean AB. Oncogene expression in cervical intraepithelial neoplasia and invasive cancer of the cervix. *Lancet* 1991; 337: 819-820

Plowman GD, Culouscou J-M, Whitney GS, Green JM, Carlton GW, Foy L, Neubauer MG, Shoyab M. Ligand-specific activation of HER4/p180erb B4, a fourth member of the epidermal growth factor family: *Proc Natl Acad Sci USA* 1993; 90: 1746-1750

Plowman GD et al. Heregulin induces tyrosine phosphorylation of HER4/p180 erbB4. *Nature*. 1993; 366: 473-5

Plowman GD, Whitney GS, Neubauer MG, Green JM, McDonald VL, Todaro GJ, Shoyab M. Molecular cloning and expression of an epidermal growth factor-related gene. *Proc Natl Acad Sci* 1990; 87: 4905-4909

Poller DN, Spendlove I, Baker C et al. Production and characterization of a polyclonal antibody to the c-erbB-3 protein: examination of c-erbB-3 protein expression in adenocarcinomas. *Nature* 1992; 168: 275-280

Popescu NC, King CR and Kraus MH. Localization of the human erbB-2 gene on normal and rearranged chromosomes 17 to bands q12-21.32. *Genomics* 1989; 4: 362-366

Powis G et al. Growth factor and oncogene signalling pathways as targets for rational anticancer drug development. *Clin Biochem*. 1991; 24: 385-97

Prenzel MF, Fischer OM, Streit S, Hart S, Ullrich A. The epidermal growth factor receptor family as a central element for the cellular signal transduction and diversification. *Endocrine Related Cancer* 2001; 8: 11-31

Prigent SA, Lemoine NR, Hughes CM, Plowmann GD, Selden C, Gullick WJ. Expression of the c-erb B-3 protein in normal human adult and fetal tissues. *Oncogene* 1992; 7: 1273-78

Prost S, Le MG, Douc RS, Ahomadegbe JC, Spielmann M, Guerin M and Riou G. Association of c-erbB2-gene amplification with poor prognosis in noninflammatory breast carcinomas but not in carcinomas of the inflammatory type. *Int J Cancer* 1994; 58: 763-768

Quinn CM, Ostrowski JL, Lane SA, Loney DP, Teasdale J, Benson FA. C-erb B-3 protein expression in human breast cancer: comparison with other tumor variables and survival. *Histopathology* 1994; 25: 247-252

Rajkumar T, Gooden CSR, Lemoine NR and Gullick WJ. Expression of the c-erbB-3 protein in gastrointestinal tract tumours determined by monoclonal antibody RTJ1. *J Pathol* 1993; 170: 271-278

Rajkumar T, Majhi U, Malligarjuna Shanta V and Gullick WJ. Prevalence of c-erb B-3 expression in squamous cell carcinomas of the cervix as determined by the monoclonal antibody RTJ2. *International Journal of Oncology*, 1995; 6: 105-109

Ralkjumar T et al. The type I growth factor receptors in human breast cancer. *Breast Cancer Res Treat*. 1994; 29: 3-9

Remmele, W. and Stegner, H.E. Immunohistochemischer Nachweis von Östrogenrezeptoren (Er-ICA) im Mammakarzinomgewebe, Vorschlag zur einheitlichen Bewertung des Untersuchungsbefundes. *Der Frauenarzt* 1987; 2: 41-43

Riese DJIII, Stern DF. Specificity within the EGF family/Erb B-Receptor family signalling network. *BioEssays* 1998; 20: 41-48

Rosty C, Couturier J, Vincent-Salomon A, Genin P, Freneaux P, Sigal-Zafrani B, Sastre-Garau X. Overexpression/amplification of HER-2/neu is uncommon in invasive carcinoma of the uterine cervix. *Int J Gynecol Pathol.* 2004 Jan; 23(1): 13-17

Rusch V, Mendelsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligands as therapeutic targets in human tumors. *Cytokine Growth Factor Rev* 1996; 7: 133-141

Salomon DS, Bianco C, De Santis M. Cripto, a novel epidermal growth factor (EGF)-related peptide in mammary gland development and neoplasia. *BioEssays* 1999; 21: 61-70

Salomon DS, Brandt R, Ciardello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. *Crit Rev Oncology Hematology* 1995; 19: 183-232

Sartor C, Zhou H, Kozłowska E, Guttridge K, Kawata E, Caskey L, Harrelson J, Hynes N, Ethier S, Calvo B, Earp HS. HER4 mediates ligand-dependent antiproliferative and differentiation responses in human breast cancer cells. *Mol Cell Biol* 2001; 21: 4265-4275

Scambia G, Ferrandina G, Distefano M, D'Agostino G, Benedetti-Panici P and Mancuso S. Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer. *Cancer Letters* 1998; 123: 135-139

Shak Steven for the Herceptin Multinational Investigator Study Group. Overview of the Trastuzumab (Herceptin) Anti-HER2 Monoclonal Antibody Clinical Program in HER2-Overexpressing Metastatic Breast Cancer. *Seminars in Oncology*, 1999, Vol 26, No 4, Suppl 12 (august): pp 71-77

Sharma A, Pratap M, Malhotra Sawhney V, Khan IU, Bhambhani S and Mitra AB. Frequent Amplification of C-erbB2 (HER-2/Neu) Oncogene in Cervical Carcinoma as Detected by Non-Fluorescence in situ Hybridization Technique on Paraffin Sections. *Oncology* 1999; 56: 83-87

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. *Science* 1987; 235: 177-182

Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. *Science* 1989; 244: 707-712

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. *N Engl J Med* 2001; 344: 783-792

Sporn MB et al. Autocrine secretion – 10 years later. *Ann Intern Med.* 1992; 117: 408-14